OLGA BROOKS SELECTED AS TOP CERTIFIED RAPID TRANSFORMATIONAL THERAPIST OF THE YEAR BY IAOTP
NEW YORK, NY, UNITED STATES, July 23, 2025 / EINPresswire.com / -- Olga Brooks was recently selected as Top Certified Rapid Transformational Therapist of the Year 2025 by the International Association of Top Professionals (IAOTP) for her outstanding leadership, dedication, and commitment to the industry.
Inclusion with the International Association of Top Professionals is an honor in itself; only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All honorees are invited to attend the IAOTP annual award gala at the end of this year for a night to honor their achievements.
www.iaotp.com /award-gala
With close to a decade of co-writing books, Olga has co-written 4 international bestselling books which began her journey into the field of self-improvement and impoverishment. Olga has proven herself as an expert in her field. As a dynamic, results-driven leader, Olga Brooks is the Founder of The Return LLC, where she has committed her life's work to helping individuals overcome fear and anxiety through a transformative blend of coaching, quantum energy healing, and therapeutic techniques. Under her leadership, The Return LLC has become a trusted sanctuary for those seeking emotional resilience, spiritual balance, and personal empowerment.
In her private practice, Ms. Brooks works closely with women, particularly those navigating major life transitions, to help them release stored negative energy and reconnect with their feminine essence. Her unique approach combines energy work with the psychological understanding of the feminine, enabling clients to break through fear, rebuild confidence, and move forward with clarity and strength.
Current and previous roles include serving as the Founder of The Return LLC since August 2018, where Olga Brooks has led clients through personal transformation using a unique combination of coaching, energy work, and therapeutic modalities. Since January 2021, she has also worked as a Quantum Energy Healer, helping individuals clear stored emotional blocks and restore energetic balance. Before founding The Return, she gained valuable experience as a consultant and distributor for Purium, a role that deepened her understanding of wellness and holistic living.
Her areas of expertise include, but are not limited to, sound reiki, fear and anxiety education, emotional wellness, and trauma healing. She is highly skilled in Rapid Transformational Therapy, hypnosis, and subconscious reprogramming, which she uses to help clients break through deep-rooted limitations. Olga also specializes in feminine energy psychology, guiding women to reconnect with their inner essence. Her work extends to public speaking and teen empowerment, and she is known for helping individuals achieve spiritual and energetic alignment through her integrative approach.
Before embarking on her career path, Ms. Brooks completed college coursework in accounting and economics in Russia. Her education continued in the U.S., where she became a certified hypnotist and a certified Rapid Transformational Therapist under Marisa Peer.
Throughout her illustrious career, Olga Brooks has received many awards and accolades and has been recognized worldwide for her accomplishments. This year she will be featured in the Wall Street Journal and she is being considered for the Empowered Woman Award and to be featured in TIP (Top Industry Professionals) Magazine. She will be honored at IAOTP's annual awards gala at the magnificent Bellagio Hotel in Las Vegas this December for her selection as Top Certified Rapid Transformational Therapist of the Year 2025.
In addition to her successful career, Ms. Brooks is actively expanding her impact by speaking at colleges and organizations about emotional resilience, mental clarity, and spiritual growth. She is also the author of the upcoming teen empowerment book 'PG13", designed to help young people and their parents reframe fear and build confidence from within.
The President of the International Association of Top Professionals (IAOTP), Stephanie Cirami, stated: 'Choosing Olga Brooks for this honor was an easy decision for our panel to make. Olga is inspirational, influential, and a true visionary and thought leader. We cannot wait to meet her and celebrate her accomplishments at this year's gala.'
Looking back, Olga attributes her success to her perseverance, work ethic, and the mentors she has had along the way. When not working, she enjoys traveling and spending time with her family. In the future, she hopes to inspire and influence those getting into the field.
For more information, please visit: linkedin.com/in/olga-brooks-b28988168
About IAOTP
The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world's finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.
IAOTP's experts have given thousands of top prestigious professionals worldwide the recognition and credibility they deserve and have helped build their branding empires. IAOTP prides itself on being a one-of-a-kind boutique networking organization that handpicks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.
For more information on IAOTP, please visit: www.iaotp.com
Stephanie Cirami
IAOTP
+1 212-634-4427
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
3 Medical Stocks to Consider as Markets Take a Breather
The broader indexes have cooled off in the last few trading sessions after what was another pleasant month for the stock market in July. While the market has been able to shrug off trade war concerns on the way to a historic rebound, President Trump has officially signed an executive order to hit most of the United States' trading partners with tariff hikes, which ignited a pullback on Friday as July's Jobs Report came in weaker than expected. Considering the benchmark S&P 500 and the tech-centric Nasdaq looked due for a breather after spiking more than +10% in the last three months, investors may be scoping out some defensive positions. That said, these medical sector stocks may continue to provide this defensive safety, as there will always be a constant need for health care. CVS Health Zacks Rank #2 (Buy) CVS Health's CVS transformation into an innovative pharmacy company with integrated offerings across the entire spectrum of pharmacy care is paying off. Thanks to strong earnings, raised guidance, and renewed investor confidence, CVS stock has surged over +30% this year but still trades at just 10X forward earnings and offers a very generous 4.28% annual dividend yield. In addition to sporting a Zacks Rank #2 (Buy), CVS stock currently checks an overall 'A' VGM Zacks Style Scores grade for the combination of Value, Growth, and Momentum. Image Source: Zacks Investment Research Johnson & Johnson Zacks Rank #2 (Buy) Pharmaceutical giant Johnson & Johnson JNJ checks the value box, with a reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield. Furthermore, investors seemed to have flocked to Johnson & Johnson stock earlier in the year during heightened market volatility, and JNJ is still up +15% in 2025 to top the S&P 500 and Nasdaq's returns of roughly +7%. Although Johnson & Johnson's growth has slowed, steady top and bottom line expansion is still in the forecast, and the medical leader has one of the most diversified business models. Having more than 275 subsidiaries, Johnson & Johnson's pipeline of drugs/treatments covers neuroscience and mental health, oncology, immunology, pulmonary hypertension, cardiovascular, rare, and infectious diseases. Image Source: Zacks Investment Research Tenet Healthcare Zacks Rank #1 (Strong Buy) We'll round out the list with Tenet Healthcare THC, an investor-owned health care services company that owns and operates general hospitals and health care facilities for urban and rural communities in numerous states. Boasting a Zacks Rank #1 (Strong Buy), THC stock is benefiting from a very pleasant trend of positive earnings estimate revisions. With Tenet Healthcare's annual earnings now expected to leap 25% in fiscal 2025 to $14.92 per share, it's noteworthy that these EPS revisions have climbed 17% in the last 60 days from estimates of $12.69 two months ago. Plus, THC is up +25% YTD and trades at 10X forward earnings. Strongly suggesting Tenet Healthcare's impressive stock performance should continue, FY26 EPS is projected to expand another 4% to $15.48, and estimates have spiked 14% in the last 60 days. On top of being a 'feel-good' investment in regard to Tenet Healthcare reaching underserved communities, THC checks the fundamental trading boxes with an 'A' VGM Zacks Style Scores grade. Image Source: Zacks Investment Research Bottom Line Hopefully, the excitement for AI-driven growth will continue to push the broader market higher, but these top medical stocks can provide the defensive safety that investors may need with volatility starting to resurface amid President Trump's tariff hikes and last month's unfavorable jobs report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
4 hours ago
- Yahoo
Justin Timberlake has Lyme disease. A doctor explains what it is
As pop star Justin Timberlake concluded his world tour earlier this week, the 'SexyBack' singer shared on Thursday in a social media post that he has been grappling with health issues and a diagnosis of Lyme disease. Timberlake did not disclose which stage of Lyme disease he is experiencing in his Instagram post relaying his diagnosis, but the singer wrote, 'At least I could understand why I would be onstage and in a massive amount of nerve pain or, just feeling crazy fatigue or sickness.' His ordeal, like that of Bella Hadid and other celebrities before him, brings up many questions. What exactly is Lyme disease, and how is it contracted and spread? How is the illness diagnosed and treated? What does it mean when someone has 'chronic Lyme'? Is there a vaccine for Lyme disease? To help us with these questions, I spoke with CNN wellness expert Dr. Leana Wen, an emergency physician and professor of health policy and management at the George Washington University Milken Institute School of Public Health. She previously served as Baltimore's health commissioner. CNN: Can you start by explaining what Lyme disease is? Dr. Leana Wen: Lyme disease is a bacterial infection. The bacterium Borrelia burgdorferi is the most common cause. In rare cases, Borrelia mayonii may cause the illness also. In the United States, Lyme is the most common disease spread by vectors, which are animals such as mosquitoes and ticks that spread infections. Lyme disease is transmitted through the bite of a particular tick, the black-legged tick (Ixodes scapularis and Ixodes pacificus). There are three stages of Lyme disease. The first stage is early localized disease that begins within a day to four weeks after the tick bite. People develop flu-like symptoms such as headache, muscle aches and fatigue. Some develop a characteristic 'bull's-eye' rash known as erythema migrans. The second stage occurs three to 12 weeks after the initial infection. This is the 'early disseminated' stage in which people have more widespread symptoms. They can include dizziness, chest pain, palpitations, arthritis and facial nerve paralysis. The third stage is 'late disseminated' disease, which can occur months after infection. Here, again, there is a constellation of symptoms. They include ongoing joint pain, fatigue, depression, palpitations, and other neurological, rheumatological and cardiac involvement. CNN: How is Lyme disease treated, and why is it important to get prompt treatment? Wen: Early diagnosis and prompt treatment can prevent complications and the progression to the next stages of disease. The standard treatment is antibiotic therapy. Most people are cured after taking oral antibiotics for 10 to 14 days. Preventive therapy is common, too. If someone has been bitten by a black-legged tick, also known as a deer tick , in an area of the country known to have Lyme, they could take one dose of the antibiotic doxycycline to prevent Lyme infection. This step should be done within 72 hours of the tick bite. It's important to carefully remove the tick if it's still attached. Take a picture and bring it with you to the doctor's appointment, or send the picture to your provider if you're having a telemedicine visit. CNN: Is there a blood test one could take to see whether they have Lyme disease? Wen: Yes, though there are several limitations. The most common tests are antibody tests, which detect antibodies the body makes in response to infection. These tests probably don't turn positive until several weeks after infection, so if someone just got infected and took the test, it will be negative even if the person has Lyme. In addition, the antibodies could persist in the blood for months or even years, but their presence alone does not signify that Lyme disease is the cause of all the symptoms a person may have. False positives also can occur, with some other tickborne diseases and autoimmune illnesses triggering a positive result in the absence of Lyme disease. CNN: Then how is Lyme disease diagnosed? Wen: Typically, it's diagnosed through a careful symptom documentation and an exposure history. Physical signs, such as the characteristic rash, enlarged lymph nodes or joint swelling, can aid in the diagnosis, as well. Blood testing can help but has limitations, as I mentioned earlier. The provider often presumptively treats with antibiotics based on the clinical history. CNN: What does it mean when someone has 'chronic Lyme'? Wen: There is a condition called post-treatment Lyme disease syndrome, or PTLDS. This refers to people who have had Lyme disease but, six months or longer after completing treatment, still have persistent symptoms. These symptoms can include fogginess, difficulty thinking, ongoing fatigue, and nerve and joint pain. It's not known why some people develop PTLDS. There are several hypotheses, including a persistent infection or autoimmune response. The symptoms of PTLDS can be treated, but there is no proven cure. The term 'chronic Lyme disease' includes people who have PTLDS. It is sometimes also used to describe symptoms in people who have not been diagnosed with Lyme disease. According to the National Institute of Allergy and Infectious Diseases, 'because of the confusion in how the term (chronic Lyme disease) is employed, and the lack of a clearly defined clinical definition, many experts in this field do not support its use.' In my experience as a physician and patient advocate, I have met many people who believe they have this condition and are really suffering. Many are debilitated as a result and unable to function as they previously did. Just like long Covid and other similar conditions, there is much that we do not understand about this condition. Far more research needs to be done in order to alleviate the very real agony and distress that these patients are experiencing. CNN: Is there a vaccine for Lyme disease? Wen: There are several vaccines against Lyme disease for dogs. For humans, there are some late-stage clinical trials that are ongoing, including one by Valneva and Pfizer that could be submitted for regulatory approval by 2025. CNN: What are ways to avoid contracting Lyme? Wen: Without a vaccine, the best way to prevent Lyme disease is to prevent tick bites. If you are going to areas where ticks known to carry Lyme are found, wear long-sleeved shirts and pants. Use insect repellent that contains DEET. Once you return indoors, examine yourself — and children and pets — for ticks. Remove the tick if found, and immediately contact your primary care provider to ask about preventive antibody treatment. And stay alert for symptoms, since early antibiotic therapy is crucial to prevent longer-term consequences. Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being. Solve the daily Crossword
Yahoo
8 hours ago
- Yahoo
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
